Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adalimumab-polyelectrolyte nanocomplexes decelerate synovial drug clearance <i>ex vivo</i>.

Nanoscale·2026
Same author

Spray-freeze-drying aprepitant with hydroxypropyl cellulose increases nasal bioavailability.

International journal of pharmaceutics: X·2026
Same author

Systematic investigation of thermal process parameters on the morphology of spray-freeze-dried powders.

Journal of colloid and interface science·2026
Same author

Liquisolids as a platform for the formulation of cannabis tablets.

International journal of pharmaceutics: X·2026
Same author

Impact of Drug Hydrophilicity on Transdermal Delivery by Nanoemulsions.

Pharmaceutics·2026
Same author

Combined extraction and spray-freeze-drying of Cannabis sativa Flos provides stable lyophilizate particles of cannabinoids.

Journal of cannabis research·2026

Related Experiment Video

Updated: Jul 1, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.8K

In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release.

Michael Uwe Hartig1,2, Jan Appelhaus1, Marc Vollenbröker2

  • 1Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.

Pharmaceutics
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

A novel biodegradable implant for neurogenic detrusor overactivity (NDO) offers a week-long treatment, reducing catheterization needs. This sustained-release formulation improves quality of life for NDO patients.

Keywords:
PLGAbiodegradablein situ forming implantin vitrointravesical deliveryoxybutynin

More Related Videos

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
03:25

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

Published on: June 16, 2022

1.3K
A Novel Surgical Technique in a Sheep Model for Suburethral Graft Implantation
13:45

A Novel Surgical Technique in a Sheep Model for Suburethral Graft Implantation

Published on: June 20, 2025

904

Related Experiment Videos

Last Updated: Jul 1, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.8K
Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
03:25

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

Published on: June 16, 2022

1.3K
A Novel Surgical Technique in a Sheep Model for Suburethral Graft Implantation
13:45

A Novel Surgical Technique in a Sheep Model for Suburethral Graft Implantation

Published on: June 20, 2025

904

Area of Science:

  • Biomaterials Science
  • Polymer Chemistry
  • Urology

Background:

  • Neurogenic detrusor overactivity (NDO) causes bladder dysfunction due to neurological conditions like spinal cord injury.
  • Current treatments involve frequent catheterization and oral medications such as oxybutynin hydrochloride.
  • There is a need for improved, less invasive treatment options for NDO patients.

Purpose of the Study:

  • To investigate a novel in situ forming implant (ISFI) for sustained release of oxybutynin hydrochloride in the urinary bladder.
  • To quantify drug release, polymer degradation, and solvent release in vitro for PLGA-based formulations.
  • To identify formulation parameters influencing drug release and polymer degradation for NDO treatment.

Main Methods:

  • Development and in vitro testing of PLGA-based ISFIs with varying drug loads and polymer terminations.
  • Quantification of oxybutynin hydrochloride release profiles over time.
  • Assessment of PLGA polymer degradation rates using different formulations and drug concentrations.
  • Evaluation of solvent release characteristics.

Main Results:

  • Drug load and PLGA termination significantly impacted drug release and polymer degradation.
  • Increased drug load (1.5% to 7.5%) enhanced PLGA degradation.
  • Oxybutynin base catalyzed polymer degradation; acid-terminated PLGA increased degradation compared to ester-terminated.
  • Formulation parameters were identified to control drug release and polymer degradation.

Conclusions:

  • A biodegradable ISFI is feasible for NDO treatment, potentially enabling single administration for up to one week.
  • This novel implant could significantly improve the quality of life for NDO patients by reducing treatment burden.
  • Understanding formulation parameters is key to optimizing drug release and polymer degradation for effective NDO therapy.